KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Gains from Equity Investments (2016 - 2018)

Inovio Pharmaceuticals' Gains from Equity Investments history spans 9 years, with the latest figure at -$228665.0 for Q3 2018.

  • For Q3 2018, Gains from Equity Investments rose 45.98% year-over-year to -$228665.0; the TTM value through Jun 2019 reached -$228665.0, up 79.85%, while the annual FY2018 figure was -$360795.0, 55.28% up from the prior year.
  • Gains from Equity Investments for Q3 2018 was -$228665.0 at Inovio Pharmaceuticals, up from -$259971.0 in the prior quarter.
  • Across five years, Gains from Equity Investments topped out at $505926.0 in Q1 2014 and bottomed at -$824390.0 in Q2 2014.
  • The 5-year median for Gains from Equity Investments is -$2691.0 (2016), against an average of -$95835.4.
  • The largest annual shift saw Gains from Equity Investments soared 33263.41% in 2016 before it plummeted 15630.06% in 2017.
  • A 5-year view of Gains from Equity Investments shows it stood at -$143659.0 in 2014, then surged by 302.09% to $290316.0 in 2015, then plummeted by 322.13% to -$644888.0 in 2016, then grew by 10.13% to -$579546.0 in 2017, then surged by 60.54% to -$228665.0 in 2018.
  • Per Business Quant, the three most recent readings for INO's Gains from Equity Investments are -$228665.0 (Q3 2018), -$259971.0 (Q2 2018), and $127841.0 (Q1 2018).